Gyre Therapeutics, Inc. (GYRE) Free cash flow 2016–2025
Gyre Therapeutics, Inc. (GYRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$180,000FY2025 · since FY2016: -$18.9M → -$180,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$180,000 | +97.0% |
| FY2024 | -$6.0M | -134.3% |
| FY2023 | $17.4M | +205.3% |
| FY2022 | $5.7M | +106.7% |
| FY2021 | -$84.6M | — |
| FY2019 | -$43.7M | -51.0% |
| FY2018 | -$28.9M | -44.9% |
| FY2017 | -$20.0M | -5.4% |
| FY2016 | -$18.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice